CurrentBlue Cross Blue Shield - IowaPolicy N/A

External Upper Limb Stimulation for the Treatment of Tremors (TAPS)

This policy governs coverage and evidence assessment for transcutaneous afferent patterned stimulation (TAPS) devices (external upper limb tremor stimulation) for treatment of essential tremor and action tremor in Parkinson disease for Blue Cross Blue Shield - Iowa members.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyExternal Upper Limb Stimulation for the Treatment of Tremors (TAPS)

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateNov 1, 2022

Next Review DateDec 1, 2025

Key ActionVerify member benefits and document baseline tremor severity and prior medication history when requesting coverage or prior authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalPolicy stance for all indications

1 RCTRCTs identified

Up to 64%Max reported tremor power reduction

18%Non-serious device-related AEs

E0734, A4542

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determination and Rationale

Investigational / Not covered with criteria

Not covered (investigational) — the following statement summarizes the policy stance.

Investigational / Not covered: Transcutaneous afferent patterned stimulation (TAPS) is considered investigational for all indications, including essential tremor and action tremor associated with Parkinson disease.

Claims for investigational services may be denied; no covered criteria are provided in this policy.

Evidence-based coverage considerations

Key evidence points and considerations informing the investigational stance:

Essential Tremor Evidence: Evidence includes one pragmatic randomized controlled trial showing reduction in device-measured tremor power and additional prospective open‑label and retrospective studies reporting functional improvements; limitations include open‑label or single‑arm designs, short follow‑up, exclusion of subjects from analysis, and lack of consensus on clinically meaningful change in clinical scales.RCT + supportive observational data

Further comparative studies versus pharmacologic therapy and trials assessing clinically meaningful functional outcomes and durability are needed.

Parkinson Disease (Action Tremor) Evidence: Evidence is limited to a prospective, open‑label, single‑arm study reporting immediate reductions in tremor power with repeated in‑home TAPS; the body of evidence lacks control groups, blinding, and long‑term outcome data.single‑arm evidence only

Insufficient comparative evidence to establish long‑term clinical benefit or superiority to established pharmacotherapy.

Clinical and Guideline Context: No guideline recommendations from major professional bodies (American Academy of Neurology) endorse TAPS for essential tremor; absence of guideline endorsement and limited comparative data support an investigational policy stance.Absence of guideline endorsement + limited comparative data

Consideration of pharmacologic comparators (e.g., propranolol, primidone) is relevant when evaluating the need for comparative trials.

Transcutaneous afferent patterned stimulation (TAPS) is investigational for all indications including essential tremor and action tremor associated with Parkinson disease.

The American Academy of Neurology (AAN) guideline for essential tremor includes recommendations for pharmacologic and surgical treatments but does not provide recommendations for TAPS.

No professional guideline-level endorsement for transcutaneous afferent patterned stimulation (TAPS) was identified in the AAN update; the guideline does not recommend TAPS as a treatment option for essential tremor.

The available evidence is limited and does not establish a net health benefit: studies include a single pragmatic randomized controlled trial and several nonrandomized or single-arm studies that showed reductions in device-measured tremor power but were open-label, short-term, and lacked robust analyses of clinically meaningful outcomes. Therefore, evidence is insufficient to determine that TAPS improves net health outcome for essential tremor or for action tremor associated with Parkinson disease.

Given the lack of comparative trials and limited long-term outcome data, TAPS should not be substituted for established pharmacologic therapies (for example, propranolol or primidone) without adequate evidence demonstrating superiority or meaningful comparative benefit.

Billing and Coding

Codes table referencedmixed

No codes listed

Durable medical equipment and supplies HCPCSHCPCSCovered

E0734	External upper limb tremor stimulator of the peripheral nerves of the wrist
A4542	Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist

CPTCPT

CPT codes not specified in this section

Provider Requirements, Prior Authorization, and Documentation

Note

Prior Approval

Prior approval is not required for this service under the payer's prior approval process. Providers should still verify member benefits and eligibility before scheduling or furnishing services as benefits may vary by contract.

Prior approval: Not applicable
Action: Verify member benefits and eligibility for each patient

Prior Authorization

Prior Authorization for TAPS Devices (DME authorization process)

Prior authorization is required for durable medical equipment (DME) claims related to transcutaneous afferent patterned stimulation (TAPS) devices when billed as HCPCS E0734 or A4542 per the payer's standard prior authorization process. When a prior authorization is requested for a TAPS device, submit clinical evidence supporting medical necessity, including documentation of tremor severity and prior treatments.

Affected HCPCS: E0734, A4542
Submit: Clinical evidence, baseline tremor severity, prior treatment history

Clinical Background

Essential tremor (ET) is the most common adult tremor disorder, typically producing a rhythmic, involuntary movement most often affecting the hands and arms. Parkinson disease can cause action tremor, which is tremor occurring with voluntary movement; treatments for these tremors include pharmacotherapy and surgical options, while TAPS is a noninvasive, wrist-worn stimulation intended to reduce tremor amplitude.

Definitions and Device Terms

TAPS — definition and mechanism

Mechanism of actionAlternating stimulation of the median and radial nerves at the wrist transmits afferent input to central tremor circuits (including the ventral intermediate nucleus of the thalamus), with the proposed effect of reducing tremor amplitude and frequency.

Delivery methodOn-demand, wrist-worn device delivering individualized electrical stimulation sessions that can be self-administered at home or used in clinic.

External upper limb tremor stimulation device (wrist-worn)

Device typeExternal upper limb tremor stimulation device — an on-demand, noninvasive, wrist-worn stimulator (examples: Cala Trio, Cala kIQ).

Intended useDelivers individualized electrical stimulation to the nerves of the arm to reduce tremor in patients with essential tremor or Parkinson disease–related action tremor.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyExternal Upper Limb Stimulation for the Treatment of Tremors (TAPS)

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateNov 1, 2022

Next Review DateDec 1, 2025

Key ActionVerify member benefits and document baseline tremor severity and prior medication history when requesting coverage or prior authorization.

SourceLink

On This Page

Note

Use of TAPS Devices (External Upper Limb)

TAPS devices are external, wrist-worn stimulators intended for upper limb tremor management. Providers must document the intended use (external upper limb tremor stimulation) and confirm that device requests are for the wrist-worn peripheral nerve stimulator configuration.

Device type: External upper limb (wrist-worn) tremor stimulator
HCPCS mapping: E0734 = device, A4542 = supplies/accessories

Documentation Required

Billing Documentation and Coding

Use appropriate HCPCS/CPT and ICD-10 diagnosis codes on claims and document the place of service. Include documentation of baseline tremor severity using validated scales (e.g., TETRAS, BF-ADL), indication, and the clinical rationale for the device. Ensure clinical records supporting the prior authorization are retained and submitted when requested.

Codes: HCPCS E0734 (device), A4542 (supplies/accessories); include relevant ICD-10 diagnosis code for essential tremor or Parkinson disease tremor
Documentation: Baseline tremor severity (TETRAS, BF-ADL), indication, prior treatment history, place of service

Denial Risk

Coding-Related Denial Risk

Missing or incorrect HCPCS or supply codes (particularly E0734 and A4542) or failure to document place of service and clinical indication may result in claim denials. Claims for investigational services may be denied if the device is requested for an indication considered investigational.

Denial risk if HCPCS E0734 or A4542 omitted or incorrect
Denial risk for investigational indications (TAPS considered investigational for ET and action tremor of PD per policy)

Note

Benefit Determination and Member Verification

Benefit determinations are based on the applicable contract language in effect when services are rendered. Providers must verify individual member benefits and plan limitations; Wellmark determines medical necessity only if the benefit exists and no contract exclusions apply.

Providers: Verify member-specific benefits and limitations before providing services
Operational note: Medical necessity determinations require that the service be a covered benefit under the member's contract

Documentation Required

First-Line Treatments and Required Prior Pharmacotherapy Documentation

First-line treatment for essential tremor includes pharmacotherapy such as propranolol and primidone. Document prior trials of first-line pharmacotherapies, including dosages, duration, response, and adverse effects, when requesting TAPS as an alternative or adjunctive therapy.

First-line agents: Propranolol, primidone
Document: Prior pharmacotherapy trials (agent, dose, duration, response, adverse effects)

Step Therapy

Pharmacotherapy Comparator and Step Therapy Context

Pharmacotherapy (e.g., propranolol) is an important comparator and is typically considered before device-based therapies. Prior authorization submissions for TAPS should include documentation of failure, intolerance, or contraindication to appropriate pharmacologic therapy when applicable.

Comparator: Pharmacologic therapy (propranolol, primidone, other agents)
Requirement: Show failure, intolerance, or contraindication to pharmacotherapy when claiming medical necessity for device

Note

Guideline Context for Step Therapy

Clinical guidelines (AAN) do not provide recommendations for TAPS as a treatment for essential tremor. The lack of guideline-level endorsement supports applying step therapy and requiring documentation of prior appropriate pharmacologic management before considering device-based options.

AAN guidance: No recommendation for TAPS in ET (2011 guideline reaffirmed July 2022)
Implication: Lack of guideline support may inform step therapy and coverage decisions

Documentation Required

Required Clinical Documentation for Prior Authorization

When requesting prior authorization or submitting claims for TAPS devices, include baseline tremor severity using validated scales (e.g., TETRAS, BF-ADL), objective device-measured tremor power if available, and a detailed prior pharmacotherapy history. Incomplete clinical documentation may lead to denial of authorization or claim payment.

Required clinical documentation: Baseline TETRAS or BF-ADL scores, prior pharmacotherapy trials, objective tremor measurements if available
Operational note: Include clinical rationale and expected benefit

Billing Rule

Prior Authorization and Billing for DME (E0734, A4542)

Claims for E0734 and A4542 follow the payer's DME prior authorization and billing processes. Ensure supplies and accessories are billed using A4542 and that device rental or purchase rules per the member contract are followed.

DME codes: E0734 (external upper limb tremor stimulator), A4542 (supplies/accessories)
Follow payer DME prior authorization and billing rules (rental vs purchase per contract)

Denial Risk

Investigational Determination and Provider Guidance

Services determined investigational by the policy (TAPS for ET and action tremor in PD) may be denied. Providers may submit clinical evidence for review, but should anticipate potential denials for investigational indications and counsel patients accordingly.

Investigational determination: TAPS considered investigational for ET and PD action tremor per policy
Provider action: Submit supporting evidence; verify likelihood of coverage before provision

TAPS — clinical restatement

Alternate phrasingTAPS — transcutaneous afferent patterned stimulation: noninvasive, wrist-worn electrical stimulation alternating between median and radial nerves and calibrated to tremor frequency.

Clinical context noteUsed in trials as a device-based intervention added to or compared with standard of care pharmacotherapy for essential tremor.

Tremor power — definition and role

DefinitionTremor power — an objective, device-derived calculation that combines tremor amplitude and frequency; lower tremor power indicates smaller amplitude and/or lower frequency movements.

Role as outcome measurePrimary device-measured endpoint in randomized and nonrandomized studies of TAPS; used to quantify immediate and longitudinal changes in tremor following stimulation.

InterpretationReported study results express percent change in tremor power (e.g., up to ~64% reduction reported in long-term database analyses and single-arm PD studies).

E0734 (device description) — HCPCS definition

HCPCS codeE0734 — External upper limb tremor stimulator of the peripheral nerves of the wrist.

Type of serviceDurable Medical Equipment (DME) — reported as HCPCS DME item in the policy coding section.

Place of servicePlace of service examples listed: Home, Inpatient, Outpatient.

A4542 (supplies/accessories) — HCPCS definition

HCPCS codeA4542 — Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist.

AssociationCode is paired with the device HCPCS (E0734) for reporting supplies/accessories needed for device use.

Type of serviceClassified under Durable Medical Equipment supplies/accessories in the policy coding section.